Symbol="KZR"
AssetType="Common Stock"
Name="Kezar Life Sciences Inc"
Description="Kezar Life Sciences, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of new small molecule therapies to address the unmet needs in immune-mediated diseases and cancer in the United States. The company is headquartered in South San Francisco, California."
CIK="1645666"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="93047000"
EBITDA="-89586000"
PERatio="None"
PEGRatio="None"
BookValue="3.202"
DividendPerShare="0"
DividendYield="0"
EPS="-1.01"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.194"
ReturnOnEquityTTM="-0.312"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.01"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="13"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.688"
EVToRevenue="-"
EVToEBITDA="-3.262"
Beta="0.118"
num_52WeekHigh="10.78"
num_52WeekLow="1.23"
num_50DayMovingAverage="2.251"
num_200DayMovingAverage="4.484"
SharesOutstanding="72693000"
DividendDate="None"
ExDividendDate="None"
symbol="KZR"
open="1.28"
high="1.41"
low="1.26"
price="1.40"
volume="254181.00"
latest_trading_day="2023-08-22"
previous_close="1.28"
change="0.12"
change_percent="9.3750%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="100"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Trending High"
value_analysis="Bullish Trend"
Aroon_change="FALSE"
Aroon_momentum="0"
Volume_recent_avg="803310"
Change_recent_avg="-0.02"
Delta_recent_avg="0.16"
Variance_recent_avg="0.08"
Change_ratio_recent_avg="-1.08"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="0"
Aroon_momentum_negative="100"
image_negative_thumbnail_id_1="496"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0109.jpeg"
image_negative_thumbnail_id_2="1112"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0145.jpeg"
image_neutral_thumbnail_id_1="540"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0059.jpeg"
image_neutral_thumbnail_id_2="571"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0028.jpeg"
image_positive_thumbnail_id_1="1005"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0167.jpeg"
image_positive_thumbnail_id_2="990"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0152.jpeg"
image_professor_thumbnail_id_1="1200"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0034.jpeg"
image_professor_thumbnail_id_2="1198"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
